The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report
Open accessAbstract
Background: Many patients with major depressive disorder (MDD) who experience full symptomatic remission after antidepressant treatment still have residual depressive symptoms. We describe the types and frequency of residual depressive symptoms and their relationship to subsequent depressive relapse after treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: Participants in primary ( n =18) and psychiatric ( n =23) practice settings were openly treated with citalopram using measurement-based care for up to 14 weeks and follow-up for up to 1 year. We assessed 943 (32.8% of 2876) participants who met criteria for remission to determine the proportions with individual residual symptoms and any of the nine DSM-IV criterion symptom domains to define a major depressive episode. At each visit, the 16-item Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR 16 ) and the self-report Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale were used to assessed depressive symptoms and side-effects respectively. Results: More than 90% of remitters had at least one residual depressive symptom (median=3). The most common were weight increase (71.3%) and mid-nocturnal insomnia (54.9%). The most common residual symptom domains were sleep disturbance (71.7%) and appetite/weight disturbance (35.9%). Those who remitted before 6 weeks had fewer residual symptoms at study exit than did later remitters. Residual sleep disturbance did not predict relapse during follow-up. Having a greater number of residual symptom domains was associated with a higher probability of relapse. Conclusions: Patients with remission of MDD after treatment with citalopram continue to experience selected residual depressive symptoms, which increase the risk of relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Less ill patients are known to have a smaller relapse risk overall (e.g. Nierenberg et al. 2010)”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Nierenberg et al. 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The foregoing cascade approach - which in tegrates aspects of misdiagnosis, non- ad herence, inadequate treatment trials, as well as implementation gaps - underscores the high prevalence of poor outcomes of depression in primary care, of which a significant percentage would be expected to meet crite ria for TRD 10,30,64,71,107,108 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Residual symptom load affects relapse risk overall (Nierenberg et al. 2010)”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Nierenberg et al. 2010
The cited source says what the claim attributes to it.
In the citing paper
“This was highlighted in the STAR * D trial, in which it was ob served that only 10% of persons 'in re mission' were fully asymptomatic 71 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [71]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Further drawbacks of existing TRD defi nitions are that they fail to take into consid eration the social, economic, anamnestic (e.g., adverse childhood experiences) and interpersonal factors which, alone or in combinations, are known to moderate antidepressant response 1,44,47,71,75- 81 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [71]
Experimental — accuracy not yet measured
In the citing paper
“They increase the risk for [10] and seem to be a prodromal symptom of relapse [11].”
From The effects of exercise on sleep in unipolar depression: a systematic review and network meta-analysis (2021) · cites this paper as [10]
In the citing paper
“A higher number of previous episodes (Berwian, Walter, Seifritz, & Huys, 2017; Kendler, Thornton, & Gardner, 2000), more residual symptoms (Berwian et al., 2017; Nierenberg et al., 2010), and failure to reach remission after acute antidepressant treatment (APA, 2010; Rush et al., 2006) are associated with a greater risk of relapse”
From Relapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study (2019) · cites this paper as Nierenberg et al., 2010
In the citing paper
“In addition, patients who had residual depression symptoms despite responding to treatment, had higher risk of recurrence (Serafini et al., 2018; Nierenberg et al., 2010; Judd et al., 1998) [19, 24, 25].”
From Predictors of recurrence of major depressive disorder (2020) · cites this paper as Nierenberg et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Development of a Rating Scale for Primary Depressive Illness
Hamilton, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationTRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968 · cited 2×
“…(HAMD17 ; Hamilton, 1960, 1967) or f5 on the 16-item Quick Inventory of Depressive Symptomatology, SelfReport (QIDS-SR16 ; Rush et al. 2003, 2006a ; Trivedi et al. 2004) or response (typically defined as 50% improvement in depression rating scale scores) have been associated with continued…”
BackgroundMethodSelf-citationJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.694 · Cited by 775
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707 · cited 3×
“Remission was defined as a score f5 on the 16-item Quick Inventory of Depressive Symptomatology, Clinician-rated (QIDS-C16 ; Rush et al. 2003, 2006a ; Trivedi et al. 2004).”
BackgroundMethodSelf-citationJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Treatments of Depression and the Functional Capacity to Work
Mintz, J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100005001 · Cited by 561
Cited by
Sorted by citations
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Morin, C. M., & Benca, R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60750-2 · Cited by 976
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationPiet, J., & Hougaard, E. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2011.05.002 · Cited by 807
Monoamine neurocircuitry in depression and strategies for new treatments
Hamon, M., & Blier, P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.009 · Cited by 674
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Segal, Z. V., Bieling, P., Young, T., MacQueen, G., Cooke, R., Martin, L., Bloch, R., & Levitan, R. D. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.168 · Cited by 429
Williams, J. M. G., Crane, C., Barnhofer, T., Brennan, K., Duggan, D. S., Fennell, M. J. V., Hackmann, A., Krusche, A., Muse, K., Von Rohr, I. R., et al. (2014) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0035036 · Cited by 420
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 400
Mansur, R. B., Brietzke, E. M., & McIntyre, R. S. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.017 · Cited by 342
Cognitive dysfunction in unipolar depression: Implications for treatment
Trivedi, M. H., & Greer, T. L. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.09.012 · Cited by 294
Self-citationLam, R. W., McIntosh, D., Wang, J., Enns, M. W., Kolivakis, T., Michalak, E. E., Sareen, J., Song, W.-Y., Kennedy, S. H., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659416 · Cited by 288
Response and remission criteria in major depression – A validation of current practice
Riedel, M. J., Möller, H., Obermeier, M., Schennach-Wolff, R., Bauer, M., Adli, M., Kronmüller, K., Nickel, T., Brieger, P., Laux, G., et al. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.03.006 · Cited by 289
McClintock, S. M., Husain, M. M., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Trivedi, M. H., Cook, I., Morris, D., Warden, D., & Rush, A. J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820ebd2c · Cited by 234
Self-citationCarney, C. E., Edinger, J. D., Kuchibhatla, M. N., Lachowski, A. M., Bogouslavsky, O., Krystal, A. D., & Shapiro, C. M. (2017) · SLEEP · doi:10.1093/sleep/zsx019 · Cited by 213
Brain-gut-microbiota axis: challenges for translation in psychiatry
Kelly, J. R., Clarke, G. A., Cryan, J. F., & Dinan, T. G. (2016) · Annals of Epidemiology · doi:10.1016/j.annepidem.2016.02.008 · Cited by 207
de Zwart, P. L., Jeronimus, B. F., & de Jonge, P. (2019) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000227 · Cited by 189
Using a pharmacogenomic algorithm to guide the treatment of depression
Hall‐Flavin, D. K., Winner, J. G., Allen, J. D., Jordan, J. J., Nesheim, R. S., Snyder, K. A., Drews, M. S., Eisterhold, L. L., Biernacka, J. M., & Mrazek, D. A. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.99 · Cited by 187
Felger, J. C., Li, L., Marvar, P. J., Woolwine, B. J., Harrison, D. G., Raison, C. L., & Miller, A. H. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.10.010 · Cited by 176
Perlis, R. H., Iosifescu, D. V., Castro, V. M., Murphy, S. N., Gainer, V. S., Minnier, J., Cai, T., Goryachev, S., Zeng, Q., Gallagher, P. J., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711000997 · Cited by 193
CLINICAL RELEVANCE OF FATIGUE AS A RESIDUAL SYMPTOM IN MAJOR DEPRESSIVE DISORDER
D, M. F. M., Ball, S. G., Nelson, J. C., Sparks, J., Konechnik, T. J., Classi, P. M., Dubé, S., & Thase, M. E. (2013) · Depression and Anxiety · doi:10.1002/da.22199 · Cited by 170
Plante, D. T., Jensen, J. E., Schoerning, L., & Winkelman, J. W. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.4 · Cited by 161
Segal, Z. V., Dimidjian, S., Beck, A., Boggs, J. M., Vanderkruik, R., Metcalf, C. A., Gallop, R., Felder, J. N., & Levy, J. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4693 · Cited by 159
Sleep Disturbances in Mood Disorders
Rumble, M. E., White, K. H., & Benca, R. M. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.07.006 · Cited by 145
Dunlop, B. W., Binder, E. B., Cubells, J. F., Goodman, M. M., Kelley, M. E., Kinkead, B., Kutner, M., Nemeroff, C. B., Newport, D. J., Owens, M. J., et al. (2012) · Trials · doi:10.1186/1745-6215-13-106 · Cited by 136
The Complex Role of Sleep in Adolescent Depression
Clarke, G. N., & Harvey, A. G. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.01.006 · Cited by 143
Psychiatric Disorders and Sleep Issues
Sutton, E. L. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.06.009 · Cited by 119
Dysfunctional astrocytic regulation of glutamate transmission in a rat model of depression
Gómez‐Galán, M., Bundel, D. D., Eeckhaut, A. V., Smolders, I. J., & Lindskog, M. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.10 · Cited by 123
Moderators of Cognitive Behavioral Treatment for Insomnia on Depression and Anxiety Outcomes
Mirchandaney, R., Barete, R., & Asarnow, L. D. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01326-3 · Cited by 130
Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive
Rush, A. J., Aaronson, S. T., & Demyttenaere, K. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418808585 · Cited by 120
Self-citationCognitive Behavioral Therapy for Insomnia in Depression
Asarnow, L. D., & Manber, R. (2019) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2019.01.009 · Cited by 115
Asarnow, L. D. (2019) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2019.12.002 · Cited by 121
Yeung, W., Chung, K., Tso, K., Zhang, S., Zhang, Z., & Ho, L. (2011) · SLEEP · doi:10.5665/sleep.1056 · Cited by 111
Li, H., Sagar, A. P., & Kéri, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.021 · Cited by 101
Predicting relapse after antidepressant withdrawal – a systematic review
Berwian, I. M., Walter, H., Seifritz, E., & Huys, Q. J. M. (2017) · Psychological Medicine · doi:10.1017/s0033291716002580 · Cited by 93
“Residual symptom load affects relapse risk overall (Nierenberg et al. 2010) and probably accounts for the impact of different definitions of remission on relapse risk (Dunlop et al. 2012).”
BackgroundInfluentialBahr, R., López, A. Q., & Rey, J. A. (2019) · PubMed Central · Cited by 102
Li, S. X., Lam, S. P., Chan, J. W. Y., Yu, M. W. M., & Wing, Y. K. (2012) · SLEEP · doi:10.5665/sleep.2008 · Cited by 103
An Open Pilot of Cognitive-Behavioral Therapy for Insomnia in Women with Postpartum Depression
Swanson, L. M., Flynn, H., Adams-Mundy, J. D., Armitage, R., & Arnedt, J. T. (2013) · Behavioral Sleep Medicine · doi:10.1080/15402002.2012.683902 · Cited by 98
Fatigue in Parkinson’s disease: report from a multidisciplinary symposium
Friedman, J. H., Beck, J. C., Chou, K. L., Clark, G., Fagundes, C. P., Goetz, C. G., Herlofson, K., Kluger, B. M., Krupp, L., Lang, A. E., et al. (2016) · npj Parkinson s Disease · doi:10.1038/npjparkd.2015.25 · Cited by 100
Webb, C. A., Cohen, Z. D., Beard, C., Forgeard, M. J. C., Peckham, A., & Björgvinsson, Þ. (2019) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000451 · Cited by 96
Corruble, E., de Bodinat, C., Belaïdi, C., & Goodwin, G. M. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000679 · Cited by 94
Insomnia and depression: clinical associations and possible mechanistic links
Vargas, I., & Perlis, M. L. (2020) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2019.11.004 · Cited by 95
Kang, L., Zhang, A., Sun, N., Liu, P., Yang, C., Li, G., Liu, Z., Wang, Y., & Zhang, K. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1913-6 · Cited by 94
Lotrich, F. E., Albusaysi, S., & Ferrell, R. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.263 · Cited by 92
Second-generation antipsychotics in the treatment of major depressive disorder: current evidence
Han, C., Wang, S., Kato, M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811901 · Cited by 92
Symptoms of anxiety and depression and risk of acute myocardial infarction: the HUNT 2 study
Gustad, L. T., Laugsand, L. E., Janszky, I., Dalen, H., & Bjerkeset, O. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht387 · Cited by 91
Aripiprazole as Adjunctive Therapy for Patients with Major Depressive Disorder
Pae, C., Forbes, A., & Patkar, A. A. (2010) · CNS Drugs · doi:10.2165/11538980-000000000-00000 · Cited by 92
Hoorelbeke, K., den Bergh, N. V., Wichers, M., & Koster, E. H. W. (2019) · Behaviour Research and Therapy · doi:10.1016/j.brat.2019.01.007 · Cited by 96
Cheng, P., Casement, M. D., Kalmbach, D. A., Castelan, A. C., & Drake, C. L. (2021) · Sleep · doi:10.1093/sleep/zsaa258 · Cited by 97
Geschwind, N., Peeters, F., Huibers, M., van Os, J., & Wichers, M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.104851 · Cited by 89
Clevenger, S. S., Malhotra, D., Dang, J., Vanle, B., & IsHak, W. W. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317737264 · Cited by 83
Dimidjian, S., Beck, A., Felder, J. N., Boggs, J. M., Gallop, R., & Segal, Z. V. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.09.004 · Cited by 87
“(STAR*D), 80e90% of patients reported at least one RDS that persisted for 12 months (Nierenberg et al., 2010).”
BackgroundResidual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse
Iovieno, N., van Nieuwenhuizen, A., Clain, A., Baer, L., & Nierenberg, A. A. (2011) · Depression and Anxiety · doi:10.1002/da.20768 · Cited by 98
Self-citationRomera, I., Pérez, V., Ciudad, A., Caballero, L., Roca, M., Polavieja, P., & Gilaberte, I. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-51 · Cited by 87
Culpepper, L., Muskin, P. R., & Stahl, S. M. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.07.001 · Cited by 77
Yohn, S. E., Collins, S. L., Contreras-Mora, H. M., Errante, E. L., Rowland, M. A., Correa, M., & Salamone, J. D. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.188 · Cited by 81
Sakurai, H., Suzuki, T., Yoshimura, K., Mimura, M., & Uchida, H. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4634-5 · Cited by 80
Epperson, C. N., Rubinow, D. R., Meltzer-Brody, S. E., Deligiannidis, K. M., Riesenberg, R. A., Krystal, A. D., Bankole, K., Huang, M., Li, H., Brown, C., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.143 · Cited by 82
Pennybaker, S. J., Niciu, M. J., Luckenbaugh, D. A., & Zarate, C. A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.026 · Cited by 76
Neurotransmitter Targeting in the Treatment of Depression
Blier, P. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12084su1c.04 · Cited by 74
Stahl, S. M. (2019) · CNS Spectrums · doi:10.1017/s1092852919001470 · Cited by 73
Paul, R., Andlauer, T. F. M., Czamara, D., Hoehn, D., Lucae, S., Pütz, B., Lewis, C. M., Uher, R., Müller‐Myhsok, B., Ising, M., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0524-4 · Cited by 72
MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS
Russo, M., Mahon, K., & Burdick, K. E. (2014) · Depression and Anxiety · doi:10.1002/da.22297 · Cited by 73
Treating insomnia in depression: insomnia related factors predict long-term depression trajectories
Bei, B., Asarnow, L. D., Krystal, A., Edinger, J. D., Buysse, D. J., & Manber, R. (2018) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000282 · Cited by 71
Carney, R. M., & Freedland, K. E. (2012) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3182405ac4 · Cited by 72
Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003614781 · Cited by 76
Gueorguieva, R., Chekroud, A. M., & Krystal, J. H. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30038-x · Cited by 67
Does insomnia treatment prevent depression?
Boland, E. M., Goldschmied, J. R., & Gehrman, P. R. (2023) · SLEEP · doi:10.1093/sleep/zsad104 · Cited by 69
Segal, Z. V., Anderson, A. K., Gulamani, T., Dinh Williams, L.-A., Desormeau, P., Ferguson, A., Walsh, K., & Farb, N. A. S. (2019) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000351 · Cited by 63
Dunlop, B. W., LoParo, D., Kinkead, B. L., Mletzko, T., Cole, S. P., Nemeroff, C. B., Mayberg, H. S., & Craighead, W. E. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18091075 · Cited by 69
Christensen, M. C., Wong, C. M. J., & Baune, B. T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00280 · Cited by 66
Predictors of recurrence in remitted late-life depression
Deng, Y., McQuoid, D. R., Potter, G. G., Steffens, D. C., Albert, K., Riddle, M., Beyer, J. L., & Taylor, W. D. (2018) · Depression and Anxiety · doi:10.1002/da.22772 · Cited by 65
Saragoussi, D., Touya, M., Haro, J. M., Jönsson, B., Knapp, M., Botrel, B., Florea, I., Loft, H., & Rive, B. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s136343 · Cited by 63
Brupbacher, G., Gerger, H., Zander-Schellenberg, T., Straus, D., Porschke, H., Gerber, M., von Känel, R., & Schmidt-Trucksäss, A. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101452 · Cited by 64
Identifying Difficult-to-Treat Depression
Gaynes, B. N. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133su1c.02 · Cited by 64
Recent advances in sleep and depression
Mirchandaney, R., Asarnow, L. D., & Kaplan, K. A. (2022) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000837 · Cited by 71
Dreimüller, N., Lieb, K., Tadić, A., Engelmann, J., Wollschläger, D., & Wagner, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.067 · Cited by 60
A critical review of pharmacotherapy for major depressive disorder.
Dupuy, J. M., Ostacher, M. J., Huffman, J., Perlis, R. H., & Nierenberg, A. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000083 · Cited by 61
Self-citationResting-State Functional Connectivity Impairment in Patients with Major Depressive Episode
Stoyanov, D., Khorev, V. S., Paunova, R., Kandilarova, S., Simeonova, D., Badarin, A., Kurkin, S., & Hramov, A. E. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192114045 · Cited by 63
Does exercise improve self-reported sleep quality in non-remitted major depressive disorder?
Rethorst, C. D., Sunderajan, P., Greer, T. L., Grannemann, B. D., Nakonezny, P. A., Carmody, T. J., & Trivedi, M. H. (2012) · Psychological Medicine · doi:10.1017/s0033291712001675 · Cited by 65
Self-citationDisruption of Neural Homeostasis as a Model of Relapse and Recurrence in Late-Life Depression
Andreescu, C., Ajilore, O., Aizenstein, H. J., Albert, K. M., Butters, M. A., Landman, B. A., Karim, H. T., Krafty, R. T., & Taylor, W. D. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.07.016 · Cited by 57
Meaklim, H., Saunders, W. J., Byrne, M. L., Junge, M. F., Varma, P., Finck, W. A., & Jackson, M. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.11.021 · Cited by 55
Vitamin D Supplementation Improves Mood in Women with Type 2 Diabetes
Penckofer, S. M., Byrn, M. A., Adams, W., Emanuele, M. A., Mumby, P. B., Kouba, J., & Wallis, D. E. (2017) · Journal of Diabetes Research · doi:10.1155/2017/8232863 · Cited by 54
Trajectories of individual symptoms in remitters versus non-remitters with depression
Sakurai, H., Uchida, H., Abe, T., Nakajima, S., Suzuki, T., Pollock, B. G., Sato, Y., & Mimura, M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.035 · Cited by 53
Zimmerman, M. A., Martinez, J. H., Attiullah, N., Friedman, M. A., Toba, C., Boerescu, D. A., & Rahgeb, M. (2011) · Depression and Anxiety · doi:10.1002/da.20870 · Cited by 52
Bélanger, L., Harvey, A. G., Fortier-Brochu, É., Beaulieu‐Bonneau, S., Eidelman, P., Talbot, L. S., Ivers, H., Hein, K., Lamy, M., Soehner, A. M., et al. (2016) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000084 · Cited by 55
Carney, C. E., Harris, A. L., Friedman, J., & Segal, Z. V. (2011) · Depression and Anxiety · doi:10.1002/da.20811 · Cited by 50
Shariq, A. S., Rosenblat, J. D., Alageel, A. A. S., Mansur, R. B., Rong, C., Ho, R., Ragguett, R., Pan, Z., Brietzke, E. M., & McIntyre, R. S. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.12.008 · Cited by 51
Sleep and Mood Disorders Among Youth
Asarnow, L. D., & Mirchandaney, R. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2020.09.003 · Cited by 52
Changes in body weight during pharmacological treatment of depression
Uher, R., Mors, O. N., Hauser, J., Rietschel, M., Maier, W., Kozel, D., Henigsberg, N., Souery, D., Placentino, A., Keers, R., et al. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000933 · Cited by 49
Harvey, A. G., Hein, K., Dong, L., Smith, F. L., Lisman, M., Yu, S. H., Rabe‐Hesketh, S., & Buysse, D. J. (2016) · Trials · doi:10.1186/s13063-016-1690-9 · Cited by 54
Berntson, J., Patel, J. S., & Stewart, J. C. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.06.008 · Cited by 51
Multi-modality: a new approach for the treatment of major depressive disorder
Richelson, E. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001605 · Cited by 52
Zhang, B., Fu, W., Guo, Y., Chen, Y., Jiang, C., Li, X., & He, K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.091 · Cited by 47
Dandekar, M. P., Luse, D., Hoffmann, C., Cotton, P. C., Peery, T., Ruiz, C., Hussey, C. S., Giridharan, V. V., Soares, J. C., Quevedo, J., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.03.074 · Cited by 49
Impact of psychotherapy on insomnia symptoms in patients with depression and multiple sclerosis
Baron, K. G., Corden, M. E., Jin, L., & Mohr, D. C. (2010) · Journal of Behavioral Medicine · doi:10.1007/s10865-010-9288-2 · Cited by 47
Xiao, L., Feng, L., Zhu, X., Feng, Y., Wu, W., Ungvari, G. S., Ng, C. H., Xiang, Y., & Wang, G. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.01.020 · Cited by 53
Harkness, K. L., Theriault, J. E., Stewart, J. G., & Bagby, R. M. (2013) · Depression and Anxiety · doi:10.1002/da.22177 · Cited by 45
Allega, O. R., Leng, X., Vaccarino, A. L., Skelly, M., Lanzini, M., Hidalgo, M. P. L., Soares, C. N., Kennedy, S. H., & Frey, B. N. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.047 · Cited by 44
Current Issues in the Use of fMRI-Based Neurofeedback to Relieve Psychiatric Symptoms
Fovet, T., Jardri, R., & Linden, D. E. J. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150619092540 · Cited by 43
Metadata
- Authors
- Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., Miyahara, S., & Rush, A. J.
- Affiliations
- Massachusetts General Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- Corresponding author
- Nierenberg, A. A.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2009-05-22
- Volume
- 40
- Issue
- 1
- Pages
- 41-50
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- PMC
- PMC5886713
- OpenAlex
- W2150325627
- Cited by
- 458
- References
- 31
- Citations by year
- 2026: 24 · 2025: 23 · 2024: 23 · 2023: 32 · 2022: 35 · 2021: 23 · 2020: 26 · 2019: 34 · 2018: 26 · 2017: 24 · 2016: 25 · 2015: 31 · 2014: 28 · 2013: 34 · 2012: 30
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Psychological Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health and Human Services
- Bristol-Myers Squibb
- University of Texas Southwestern Medical Center
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01 MH090003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, residual depressive symptoms, remission, citalopram, relapse risk, sleep disorders, weight gain, antidepressant side effects, STAR*D trial, QIDS-SR16
- MeSH terms
- Adult, Major Depressive Disorder, Female, Follow-Up Studies, Humans, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Personality Inventory, Psychometrics, Recurrence, Risk Factors, Citalopram, Weight Gain, Cognitive Behavioral Therapy, Antidepressive Agents, Second-Generation, Kaplan-Meier Estimate, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
